Shexiang Baoxin Pill (MUSKARDIA) reduces major adverse cardiovascular events in women with stable coronary artery disease: A subgroup analysis of a phase IV randomized clinical trial

Shexiang Baoxin Pill (MUSKARDIA) reduces major adverse cardiovascular events in women with stable coronary artery disease: A subgroup analysis of a phase IV randomized clinical trial

BackgroundA previous phase IV trial revealed sex as a potential effect modifier of MUSKARDIA efficacy in stable coronary artery disease (CAD).ObjectiveTo assess the clinical effect of MUSKARDIA as a supplemental treatment to optimal medical therapy (OMT) in stable CAD cases.MethodsThis study was a s...

Full description

Bibliographic Details
Main Authors: Haiming Shi, Jingmin Zhou, Changsheng Ma, Fusui Ji, Yang Wu, Yulan Zhao, Jun Qian, Xiaolong Wang
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-10-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
MUSKARDIA
women
stable coronary artery disease
angina
major adverse cardiovascular event
Online Access:https://www.frontiersin.org/articles/10.3389/fcvm.2022.1002400/full

Internet

https://www.frontiersin.org/articles/10.3389/fcvm.2022.1002400/full

Similar Items